Conference begins
  • No dates present

Industry-Supported Symposia

Wednesday July 6

Sanofi Genzyme

12:00-13:30

Room: Grand Ballroom Centre

Luncheon Symposium supported by Sanofi Genzyme

Pompe Medical Expert Symposium

Chair & Moderator: Dr. Vera Bril

  • Introduction of Late Onset Pompe Disease: Dr. Mark Tarnopolsky, McMaster University, Hamilton, ON
  • Diagnostic Strategies of LGMW Including Next Generation Sequencing: Dr. Matthew Harms, Columbia University, New York, NY

See here for more details.

17:15-18:15

Room: Osgoode Ballroom West

Evening Symposium supported by Akashi Therapeutics

Multi-pathway Approach to DMD Treatment

Chair: Diana Escolar

  • Antifibrotics: HT-100 For The Treatment Of DMD: Diana Escolar, MD, Chief Medical Officer, Akashi Therapeutics, Inc.
  • Modulating Calcium Homeostasis: AT-300 Effects In MDX Model Of DMD: Ernest D. Bush, Ph.D, Chief Scientific Officer, Akashi Therapeutics, Inc.
  • A Novel Approach To Building Muscle In DMD: DT-200, Selective Androgen Receptor Modulator: Diana Escolar, MD, Chief Medical Officer, Akashi Therapeutics, Inc.

See here for more details.

 

 

Thursday July 7

7:00-8:00

Room: Grand Ballroom West

Breakfast Symposium supported by Terumo BCT

The immunomodulatory role of plasma exchange in PNS & Neuromuscular diseases: A Presentation & clinical debate

  • Plasma exchange immune-modulation & mechanism of action: Prof. Hans-Peter Hartung, Heinrich-Heine-Universität, Düsseldorf, Germany
  • Clinical debate on the place of plasma exchange in PNS & neuromuscular diseases (acute & chronic), addressing current evidence & unmet medical needs:
    • Prof. Jean-Marc Leger, MD, FAAN, University Hospital Pitié-Salpêtrière, Paris, France
    • Prof. Mazen Dimachkie, University of Kansas Medical Center, Kansas City, KS

See here for more details.

7:00-8:00

Room: Osgoode Ballroom East

Breakfast Symposium supported by CSL Behring

Updates in Myasthenia Gravis

Chair: Dr. Vera Bril

  • Novel Clinical Assessment Methods in Myasthenia Gravis: Dr. Carolina Barnett, University Health Network and University of Toronto, ON
  • Recent Updates in the Treatment of Myasthenia Gravis: Dr. Zaeem A. Siddiqi, University of Alberta Hospital, Edmonton, AB

See here for more details and to RSVP.

7:00-8:00

Room: Osgoode Ballroom West

Breakfast Symposium supported by Idera

Advances in Myositis: Immune Mechanisms of Disease, Current Clinical Practice and Future Directions

Moderator: Kirsten Gruis, MD, Senior Medical Director, Rare Diseases, Idera Pharmaceuticals

  • Toll-Like Receptors and Innate Immune Mechanisms of Muscle Disease: Kanneboyina Nagaraju, DVM, PhD, George Washington University School of Medicine and Health Sciences; Children’s National Medical Center, Washington, DC
  • Current Understanding of Standards of Care and Management of Inflammatory Myopathies: Anthony A. Amato, MD, Brigham and Women’s Hospital; Harvard Medical School, Boston, MA

See here for more details and to RSVP.

Alnylam 17:15-18:15

Room: Osgoode Ballroom West

Evening Symposium supported by Alnylam

The Patient Journey: From symptom onset to new treatment horizons in hereditary ATTR amyloidosis with polyneuropathy (hATTR-PN)

  • Patient journey and unmet medical needs in hATTR-PN
  • Natural history, treatment options and clinical assessment tools in hATTR-PN
  • Development of RNAi therapeutics as a potential treatment option for patients wtih hATTR-PN

Presenters:

  • Michelle Mezei, MD (Canada)
  • P James Dyck, MD (USA)
  • Alejandra Gonzalez Duarte, MD (Mexico)

See here for more details.

Friday July 8

12:00-13:30

Room: Osgoode Ballroom West

Luncheon Symposium supported by PTC Therapeutics

The Evolving Management of Duchenne Muscular Dystrophy

Chair: Jean K. Mah

  • The Evolving Understanding of Clinical End Points and Meaningfulness: Jean K. Mah, MD, MSc, FRCPC, University of Calgary; Alberta Children's Hospital, Calgary, AB
  • The Future of Duchenne Treatments: Perry Shieh, MD, PhD, David Geffen School of Medicine at UCLA, Los Angeles, CA

See here for more details and to RSVP.

 

 

Saturday July 9

7:00-8:00

Room: Grand Ballroom West

Breakfast Symposium supported by Alexion

Recognizing the Patient with Refractory Myasthenia Gravis: An Interactive Workshop

Moderator: Karen Gondek

  • Refractory MG
  • Assessment tools and MG‐ADL

Presenters:

  • Srikanth Muppidi, MD, Stanford School of Medicine, Stanford, CA
  • Richard J. Nowak, MD, MS, Yale School of Medicine, New Haven, CT
  • Nicholas J. Silvestri, MD, University at Buffalo School of Medicine and Biomedical Sciences, Buffalo, NY
  • Gil I. Wolfe, MD, FAAN, University at Buffalo School of Medicine and Biomedical Sciences, Buffalo, NY

See here for more details.

Grifols7:00-8:00

Room: Osgoode Ballroom West

Breakfast Symposium supported by Grifols

Measuring response and need to continue treatment in CIDP: Moving from ICE trial outcome measures to future clinical biomarker

Chair: Hans Katzberg, MD

  • Residual conduction block after IVIG as a predictor of relapse in CIDP: Norman Latov, MD, Weill Cornell Medical Center, New York, NY
  • Real-time ultrasound monitoring of same lesions as a biomarker of therapeutic efficacy in CIDP: Francis Walker, MD, Wake Forest University, Winston-Salem, NC

See here for more details.

12:00-13:30

Room: Grand Ballroom West

Luncheon Symposium supported by Santhera

Advances in pulmonary care in DMD

Chair: Oscar H Mayer

  • Overview of respiratory function measures: Oscar H Mayer, The Children's Hospital of Philadelphia, PA
  • The natural history of respiratory functional decline in DMD: Erik Henricson, Physical Medicine and Rehabilitation Neuromuscular Research Center, Sacramento, CA
  • Current standards of care and future perspectives: Oscar H Mayer
  • Treatment strategies to slow decline in respiratory function in DMD - Report of the DELOS Phase III trial: Gunnar Buyse, University of Leuven, Belgium

See here for more details.

Tweets by @ICNMD2016

Follow ICNMD 2016:

Twitter

CONFERENCE NEWSLETTER

Switch To Full Site